கேலிக்குறியவர்களே அமெரிக்காவை கேலி செயது கொண்டிருக்கிற அவலம்....

கேலிக்குறியவர்களே  அமெரிக்காவை கேலி செயது கொண்டிருக்கிற அவலம்....


அமெரிக்கா, உலகின் வல்லரசு நாடுகளில்  தனித்து நிற்கும் நாடு. உயரிய அறிவியல் நுட்பங்களில் செறிவுற்ற  நாடு. உலகப் போலீஸ்காரன் என்ற ப்ட்டம்  பெற்ற நாடு.  மற்ற நாட்டுமக்களை அமெரிக்காவா என்று வாய்பிளந்து வைக்ககூடிய நாடு.... இப்படி எல்லாம் பலவிதங்களில் பெருமையாக பேசக் கூடியநாடு. இயற்கையோடு எப்போதும் போராடிக் கொண்டு இருக்கும் நாடு.... இந்த கரோனா வைரஸால் மிகவும் பாதிப்பிற்கு உட்பட்டு இருக்கிறது.அமெரிக்காவில் ஒவ்வொரு நாளும் பாதிக்கப் பட்டவர்களின் எண்ணிக்கை மட்டுமல்ல . உயிர் இழப்புகளும் அதிகமாகிக் கொண்டே போகின்றன.

அமெரிக்க செயலிலந்து விட்டதா அமெரிக்காவிற்கு என்ன ஆச்சு என்று முன்றாம்தர நாடுகள் கூட கேட்கும் ஒரு நிலமை தோன்று இருக்கிறது.  அதுதான் உண்மை.இதுதான் சாக்கு என்று அமெரிக்கவின் மீது காழ்புணர்வு கொணடவர்கள் பலர் இப்போது அமெரிக்காவின் நிலைமையை பார்த்து கேலி செய்ய ஆரம்பிக்கின்றனர்.காரணம் இந்தியாவை மிரட்டி மருத்துகளை வாங்குகிறதாம்... என்னவோ இந்த மருந்தை இந்தியாதான் கண்டுபிடித்தது போல.....

சரி இவர்களின் கிண்டல்களை கேலிகளை ஒரு புறமாக வைத்துவிட்டு அமெரிக்காவிற்கு ஏன் இந்த நிலை என்று பார்ப்போம்

 அமெரிக்க மக்களுக்குச் சரியான தகவல்கள் சரியான நேரத்தில் போய்ச் சேரவில்லை.லேட்டாக கிடைத்த தகவல்களும் ஆளும் தலைமைக்கு புரியும்படி சேரவில்லை அதுதான்  பிரதான காரணம்.

கரோனா தொடங்கிய தொடக்கக் காலத்தில் கரோனாவைப் பற்றிய முழுமையான தகவல்கள் மக்களுக்குப் போய் சேர்ந்து இருந்தால், அமெரிக்காவில் நிலைமை இந்த அளவுக்கு மோசமாகிப் போய் இருக்காது.

சீனாவின் ஹூபே மாநிலத்தின் வுஹான் நகரில் கரோனா வைரஸ் பாதிப்பு தீவிரம் அடைந்த காலக் கட்டம்.  ஜனவரி 15 2020ஆம் தேதி தான் ஐ.நா.விற்கும் உலக ஹெல்த் ஆர்கனைசேசனுக்கும் சீனா அதைப் பற்றி எச்சரிக்கை செய்தது. இந்த எச்சரிக்கைக்குப் பின்னர் சீனாவில் இருந்த அமெரிக்கர்கள் கூட்டம் கூட்டமாக  அமெரிக்காவிற்குக் திரும்ப வர ஆரம்பித்துவிட்டார்கள் . இப்படி விமானம் மூலம் அமெரிக்கா வந்தவர்களின் எண்ணிக்கை 437,000 பேர் அதாவது நான்கு இலட்சத்து முப்பத்திஏழாயிரம் பேர். அப்படி ஆயிரக் கணக்கான விமானங்களில் பறந்து போய் வந்தவர்கள்  பெரும்பாலோர் கரோனா வைரஸையும் தங்களுடன் அழைத்துச் வந்து இருக்கிறார்கள். அதுவும் கரோனாவின் கோட்டையாக விளங்கிய வுஹான் நகரில் இருந்து பல ஆயிரம் அமெரிக்கர்கள் நேரடி விமானங்கள் மூலமாக அமெரிக்காவிற்குச் வந்து இருக்கிறார்கள்.

2020 பிப்ரவரி மாதத்தில் சீனாவில் இருந்து 1,300 க்கும் அதிகமான விமானங்கள் அமெரிக்காவின் பல முக்கிய நகரங்களுக்குப் போய் இருக்கின்றன. அதில் லாஸ் ஏஞ்சல்ஸ், சான் பிரான்சிஸ்கோ, நியூயார்க், சிகாகோ, சியாட்டில், நெவார்க்; டெட்ராய்ட் போன்ற முக்கிய நகரங்கள் ஆகும்

எப்படி அமெரிக்காவில் இல்லீகல் இமிகிரேஷன் மக்கள் வந்து குவிகிறார்களோ அது போல கரோனோவும் இங்கு வந்து குவிந்துவிட்டது


கரோனாவின் வீரியக் கொடுமைத் தன்மையைப் பற்றி அமெரிக்க அதிபர் டிரம்ப்  "புரிந்து" தடைகளை விதிப்பதற்கு  முன்பாகவே சீனாவில் இருந்து நான்கு இலட்சத்திற்கும் மேற்பட்டவர்கள் அமெரிக்காவிற்குப் வந்து விட்டார்கள். அந்த நேரத்தில்  அமெரிக்க விமான நிலையங்களில் கரோனா குறித்த   மருத்துவபரிசோதனைகளில் தீவிரம் இல்லை.  வழக்கமான இமிகிரேஷன் பயண விதி முறைகள் மட்டும்தான்..

அது சரி அமெரிக்கதான் வல்லரசு நாடச்சே இதனை முதலிலியே அறிந்து தடுத்து இருக்கலாமே என்றால் இங்குதான் விதி விளையாடிக் கொண்டிருக்கிறது... இங்கு எங்களுக்கு இப்ப வாய்த்து இருக்கும் தலைவர் மோடிக்கு அண்ணன் ஆவார்.... அவருக்கு இது எல்லாம் ஒர் சாதாரண விஷயமாக இருந்திருக்கிறது அதுமட்டுமல்ல  நவம்பரில் வரப் போகும் தேர்தல் மட்டுமே கண்ணுக்குள் தெரிந்து இருக்கிறது.... அதனால்தான் இவ்வளவு பிரச்சனை.....

ஆனால் ஒன்று சொல்லவேண்டும் இங்கு தலைமைதான் சரியில்லை ஆனால் சிஸ்டம் சரியாக இருப்பதால் அந்தெந்த மாநில கவர்னர்கள் கடும் முயற்சியில் இறங்கி பணியாற்றிக் கொண்டிருக்கிறார்கள் அது மட்டுமல்ல மருத்துவ உலகமும் ஆராய்ச்சி துறைகள் சார்ந்த நிறுவனங்களும் இராப்பகலாக செயலாற்றி வருகிறார்கள்

இப்படி நடந்து கொண்ட போதிலும் பாதிப்புக்கள் என்னவோ  குறைந்த பாடில்லை.... இதை பார்த்த அமெரிக்காவின் மீது காழ்ப்புள்ளவர்கள் கேலியும் கிண்டலும் செய்கிறார்கள் .. அவர்களுக்கு  நண்பர் சிவா நடராஜ் சொன்னதை  என் தமிழில் மொழி பெயர்த்து இங்கே அப்படியே  தருகிறேன்

 ///எனது அமெரிக்கரல்லாத நண்பர்கள் அனைவரும் அமெரிக்காவை  கேலி செய்கிறார்கள், வல்லரசான அமெரிக்கா எப்படி இந்தியாவிடம்  மருந்து போன்றவற்றைக் கேட்கிறது என்பதும் அவர்களுக்கு கேலியாக இருக்கிறது. அப்படிப்பட்டவர்களுக்கு ஒன்றை நினைவுபடுத்த விரும்புகிறேன் இப்போது உலகைக் காப்பாற்றும் பெரும்பான்மையான மருத்துவம் மற்றும் மருந்துக்கள் அமெரிக்காவிலிருந்து வெளிவந்தது. மீதி ஜப்பான், பிரான்ஸ், ஜெர்மனி, இங்கிலாந்து அல்லது சுவிட்சர்லாந்திலிருந்து வந்தது.

இப்படி இவர்கள் கண்டுபிடித்த மருந்துக்களுக்கான  செலவினத்தை மிச்சப்படுத்த இந்தியா, சீனா மற்றும் ரஷ்யாவிற்கு அவுட்சோர்ஸ் செய்யப்பட்ட மருத்துவ உற்பத்தி மட்டுமே

ஒன்றை மட்டும் ஒத்துக்கொள்கிறோம் மருத்துவம் அல்லது தொற்றுநோயைப் பற்றி எதுவும் தெரியாத ஒரு தலைவர்தான் எங்களை ஆண்டுக் கொண்டிருக்கிறார், மேலும் இன்று உலகம் முழுவதும் எங்களை  பார்த்து சிரிக்கவும் வைக்கிறார். ஆனால் அமெரிக்க கண்டுபிடிப்புகளை பார்த்து சிரிக்க கொஞ்சமும் எண்ணக் கூட  வேண்டாம்.

ஒன்று மட்டும் சொல்லுகிறேன்  இந்த கரோனோ வைரஸை கட்டுபடுத்த  பயன்படுத்தக்கூடிய முதல் தடுப்பூசி ஒரு அமெரிக்க நிறுவனத்திலிருந்து வெளிவரும். உலகெங்கிலும் உள்ள உயிர்களைக் காப்பாற்ற அமெரிக்கா என்ன செய்திருக்கிறது என்பதை கொஞ்சமாவது அறிந்து அதற்கு நன்றி சொல்லுங்கள்.


ஒரு மருந்து கண்டுபிடிப்பைக் கொண்டுவர $ 3B (பில்லியன் டாலர்) அளவிற்கு செலவாகும். அப்படியும்  மருந்து ஆராய்ச்சி 95% தோல்வியடைகிறது.  இந்த ஒவ்வொரு தோல்விக்கும்  3B செலவாகிறது . இப்படிபட்ட ரிஸ்கை யார் எடுத்துக்கொள்கிறார்கள் எத்தனை நாடுகள் கேலிக்குரியவர்களே  அமெரிக்காவைக் கேலி செய்து கொண்டிருக்கிற அவலம்....

It's funny how all my non American friends are making fun of USA for the chaos we are in, and how US begs for medicine etc.. Just a reminder folks. Majority of medicine that are saving the world right now came out of America. Rest came from Japan, France, Germany, UK or Switzerland. It's just the production of medicine that was outsourced to India, China and Russia to save cost. Yes we have a leader who has no idea about medicine or pandemic and making us a laughing stock around the world. But don't count American innovation out.

I bet the first usable vaccine will come out of an American company. So be thankful to what America has done to save the lives around the world.

Or you better shut the F. up!!!\  WrittenBy Siva Nataraj



கடந்த அரை நூற்றாண்டில், உலகின் பெரும்பாலான உயிரியல் மருத்துவ கண்டுபிடிப்புகளின் பிறப்பிடமாக அமெரிக்கா இருந்து வருகிறது.  புதிய மருத்துவ தலையீடுகளின் வளர்ச்சியில் உலகளாவிய மந்தநிலை இருந்தபோதிலும், மிகவும் சிக்கலான உயிரியல் சிகிச்சைகள் குறித்த விஞ்ஞான மாற்றத்தின் காரணமாக, அமெரிக்காவில் புதுமை( innovations) ஆராய்ச்சி மற்றும் மேம்பாட்டில் (ஆர் & டி) முதலீடு செய்வதற்கான வலுவான நிதி ஊக்கங்களுக்கு நாம் நன்றிதான் சொல்ல வேண்டும் . உண்மையில், சுவிட்சர்லாந்து மற்றும் இங்கிலாந்தின்  குறைந்த கார்ப்பரேட் வரி விகிதங்களைச் சாதகமாக்க அமெரிக்க நிறுவனங்கள் தங்கள் தலைமையகத்தை சுவிட்சர்லாந்து மற்றும் இங்கிலாந்துக்கு மாற்றியதன் விளைவாகக் கடந்த இரண்டு தசாப்தங்களில் மருந்தியல் முன்னேற்றங்களுக்கு அமெரிக்க பங்களிப்புளிப்பு குறைந்தது போல ஒரு தோற்றமளிக்க கூடும் / கீழேயுள்ள விளக்கப்படத்தைப் பார்க்கும் போது குறைத்து மதிப்பிடக்கூடும். ஆனால் வரிவிகிதங்களுக்காக மட்டுமே அமெரிக்க நிறுவனங்கள் மற்றைய நாடுகளில் தங்கள் நிறுவனங்களை நிறுவி ஆராய்ச்சி செய்து வருகின்றது

அமெரிக்க போன்ற மேலை நாடுகள் இப்படி ஆராய்ச்சிக்கு பில்லியின் கணக்கில் செலவிடும்  போது அதைக் கேலி செய்பவர்களே உங்களின் தலைமை எப்படி ஆராய்ச்சிகள் செய்து கொண்டிருக்கிறது என்று சிறிதாவது யோசித்துப் பாருங்கள்... உங்கள் ஆராய்ச்சி எல்லாம் கோமியத்தின் பலன்கள் கைதட்டுவதால் ஏற்படும் பலன்,  விளக்கு ஏற்றுவதால் ஏற்படும் நன்மைகள், 9 கிரகங்களும் 9 நிமிடம் ஒரே நேர் கோட்டில் வருவதால் நடக்கும் அற்புதங்கள் என்று ஆராய்ச்சி செய்து கொண்டிருக்கிறது... இப்படிப்பட்டவர்கள் அமெரிக்காவைப் பார்த்து கேலி செய்ய என்ன தகுதி இருக்கிறது....

அமெரிக்க போன்ற நாடுகளால் தடை செய்யப்பட்ட மருந்துகளையும் எக்ஸ்பரியான மருந்துகளையும் வாங்கி சாப்பிட்டுக் கொண்டிருக்கும் இண்டியன்ஸ்கள் தான் அமெரிக்காவைக் கேலி செய்கிறார்கள்

CORONAVIRUS NEWS

New Jersey biotech Celularity, which is developing experimental cancer treatments derived from human placentas, is starting human testing of its lead immunotherapy for cases of COVID-19 disease.

Johnson & Johnson (NYSE: JNJ) announced that it has selected a lead COVID-19 vaccine candidate that it expects to start testing in humans by September.

Medical device giant Medtronic (NYSE: MDT) made design specifications of one of its ventilators publicly available in hopes of sparking others to develop ventilator technologies for treating COVID-19.

The FDA authorized a COVID-19 test designed by Abbott (NYSE: ABT) that can provide positive results in as little as five minutes and negative results in about 13 minutes. The portable test is designed to offer rapid results in healthcare settings.

Amgen (NASDAQ: AMGN) and Adaptive Biotechnologies (NASDAQ: ADPT) are partnering to discover and develop antibodies that target SARS-CoV-2 to potentially prevent or treat COVID-19.

Vir Biotechnology (NASDAQ: VIR) CEO George Scangos spoke with Xconomy sister publication Scrip to discuss his company’s work and his role leading the Biotechnology Innovation Organization’s coronavirus response.

Generation Bio and Vir announced a collaborative research agreement to bring together Generation’s non-viral gene therapy platform and Vir’s monoclonal antibodies to develop potential treatments for COVID-19.

Vir is also expanding an existing collaboration with Alnylam Pharmaceuticals (NASDAQ: ALNY) to develop RNA interference drugs for infectious diseases, including the novel coronavirus.

கேலி செய்யும் முட்டாள்களே  நீங்கள் கோமியத்தை ரிசர்ச் செய்து கொண்டிருக்கும் வேலையில் அமெரிக்கா என்ன செய்துகொண்டிருக்கிறது என்பதற்கு சாம்பிள் இதோ

Forbes will continue to update this list of private companies and how they are stepping up to fight the COVID-19 pandemic:

Testing:

Abbott Laboratories: Abbott Park, Illinois healthcare firm obtained emergency FDA authorization for its 5-minute coronavirus testing kit on March 27, with plans to start manufacturing 50,000 kits a day.

Alphabet: Through its healthcare arm Verily, Google’s parent company launched a website where users can find nearby testing sites in four California counties.

PROMOTED
Jeff Bezos.

Jeff Bezos. AFP via Getty Images

Amazon: Jeff Bezos’ retail behemoth invested $20 million in the Amazon Web Services Diagnostic Initiative, which aims to speed up delivery of COVID-19 tests to the market.

BioMérieux: French biotech company, founded by billionaire Alain Mérieux, received emergency FDA approval for its subsidiary’s new testing kit, which cuts testing times for the virus down to 45 minutes.

Carbon: California-based 3D printing unicorn backed by Russian tech investor Yuri Milner will soon be distributing testing swabs and face shields to hospitals in the Bay Area.

Cellex: North Carolina biopharma firm’s antibody-based test for COVID-19 received emergency approval from the FDA.

Cepheid: Sunnyvale, California molecular diagnostics company gained emergency FDA authorization for its new 45-minute COVID-19 testing kit.

Copan Diagnostics: Family-owned company located at the heart of Italy’s hard-hit Lombardy region makes diagnostic swabs for testing, airlifting 500,000 swabs to the U.S.

Credo Diagnostics: Singapore-based biomedical firm developed a new 20-minute coronavirus testing kit, which has been approved by European regulators and will be distributed by Italian pharma firm Menarini.

DiaSorin: Italian biotech company owned by billionaire Gustavo Denegri obtained emergency authorization from the FDA for its new 60-minute testing kit for COVID-19.

Ipsum Diagnostics: Sandy Springs, Georgia diagnostic company gained emergency FDA authorization for its COVID-19 testing kit.

Mammoth Biosciences: South San Francisco-based biotech startup, founded by three 30 Under 30 alums, prototyped a rapid test by using the gene-editing tool Crispr to detect the disease.

Mesa Biotech: San Diego biotech business obtained FDA approval for its new 30-minute testing kit for COVID-19.

Puritan Medical Products: Maine-based diagnostic maker, one of the world’s largest makers of diagnostic swabs along with Italy’s Copan Diagnostics, is reportedly increasing production to make one million COVID-19 testing swabs a week.

QIAGEN: Hilden, Germany-based molecular diagnostics firm received emergency approval from the FDA for its new COVID-19 testing kit.

Siemens Healthineers: The German conglomerate’s healthcare unit received FDA clearance for its blood gas analyzer, which helps doctors monitor the conditions of critical COVID-19 patients in ICUs.

Treatments:

AbbVie: North Chicago-based, publicly traded pharma firm is collaborating with authorities in the EU, the U.S. and China on experimental use of its HIV drug lopinavir/ritonavir to treat COVID-19.

AIM Immunotech: Florida-based pharmaceutical company announced on March 9 it would begin experimental testing of its chronic fatigue syndrome drug rintatolimod as a treatment for COVID-19 in Japan, at the National Institute of Infectious Diseases and the University of Tokyo.

AlloVir: Houston-based cell and gene therapy company is collaborating with Baylor College of Medicine to discover and develop T-cell therapies to fight COVID-19.

Amgen: Thousand Oaks, California biotech outfit is working with Seattle-based Adaptive Technologies to develop antibody-based treatments for COVID-19.

Ampio Pharmaceuticals: Englewood, Colorado biopharma company is studying the use of a nebulized form of its osteoarthritis drug ampion as a treatment against COVID-19.

Apeiron Biologics: Vienna, Austria-based biotech firm announced it would begin a trial of its immunotherapy treatment on 200 COVID-19 patients in Austria, Germany and Denmark.

APEPTICO: Austrian biotech company received approval from Austrian regulators to begin trials of its pulmonary dysfunction drug solnatide on COVID-19 patients under a compassionate use program.

Applied Therapeutics: New York-based biopharma outfit is conducting trials of its lung inflammation and cardiomyopathy drug, AT-001, on COVID-19 patients at several hospitals in New York City, including Mount Sinai.

Ascletis: Hangzhou, China pharmaceutical company announced results of clinical trials of its antiviral drug danoprevir on COVID-19 patients in China; the small-scale study found that “danoprevir combined with ritonavir is safe and well tolerated in all patients.”

AstraZeneca: British-Swedish pharma multinational is researching antibody-based treatments for COVID-19.

Can-Fite: Petah Tikva, Israel-based biotech outfit is testing its psoriasis drug piclidenoson to treat COVID-19 patients under a compassionate use program in Israel.

Celltrion: South Korean healthcare firm is developing an antiviral treatment for COVID-19, with plans to start human trials in July; the company is also developing rapid self-testing kits that would provide results within fifteen to twenty minutes, expected by the summer.

Celularity: New Jersey-based therapeutics startup obtained FDA clearance to begin trials of a potential stem cell treatment against COVID-19.

Cocrystal Pharma: Bothell, Washington pharma outfit is developing antivirals to treat COVID-19 using patents it recently acquired from the Kansas State University Research Foundation.

CytoDyn: Vancouver, Washington biotech firm announced preliminary results from three days of testing its antiviral drug leronlimab on COVID-19 patients in New York; the company stated in a press release that “test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab.”

Eli Lilly: Indianapolis pharma company is partnering with Vancouver-based biotech outfit AbCellera to develop antibody-based treatments for COVID-19.

Emergent BioSolutions: Maryland drugmaker is developing treatments derived from the antibodies found in the blood of people who tested positive for the disease.

EUSA Pharma: British pharmaceutical firm initiated trials of its siltuximab antibody treatment on COVID-19 patients at the Papa Giovanni XXIII hospital in Bergamo, Italy; the company released initial data on April 1 showing that one third of patients “experienced clinical improvement with reduced need for oxygen support” and a further 43% “saw their disease stabilise.”

Faron Pharmaceuticals: Finnish drug developer received approval from Finnish regulators to begin trials of its drug interferon beta-1a to treat COVID-19 patients in Europe, Asia and North America, excluding the U.S.

Fujifilm: Tokyo-based conglomerate’s pharmaceutical arm, Fujifilm Toyama Chemical, recently started phase 3 clinical trials of its flu drug favipiravir on COVID-19 patients in Japan and is accelerating production.

Gilead: The Californian biotech giant initiated clinical trials in March for its antiviral drug remdesivir on patients in the U.S.

Green Cross: South Korean biopharma company’s subsidiary GC Lab Cell is developing cell therapy-based treatments for COVID-19, with plans to begin human trials in the second half of the year.

Grifols: Spanish pharmaceutical company is working with the FDA and the U.S. Department of Health and Human Services to develop a COVID-19 treatment using the blood plasma of former patients.

Harbour BioMed: Cambridge, Massachusetts biomedical firm announced a collaboration with New York’s Mount Sinai Health System to develop new human antibodies to treat COVID-19.

Humanigen: Burlingame, California pharma company received emergency FDA approval for compassionate use of its antibody lenzilumab in COVID-19 patients.

I-Mab Biopharma: Shanghai-based biopharma outfit announced it would begin clinical trials of its TJM2 antibody treatment on COVID-19 patients in the United States, with plans to expand to other countries affected by the pandemic.

Incyte: Delaware-based pharmaceutical firm is planning to begin phase 3 clinical trials of its myelofibrosis drug ruxolitinib on COVID-19 patients in the U.S.

InflaRx: German drugmaker is testing its IFX-1 antibody treatment on COVID-19 patients in the Netherlands; initial studies on patients in China drew positive results.

Innovation Pharmaceuticals: Wakefield, Massachusetts biopharma firm is researching the use of its drug brilacidin — part of a category of investigational new drugs called defensin mimetics, which could have antimicrobial effects — as both a treatment and a vaccine for COVID-19, in separate efforts with a “major U.S. university” and with the Department of Health and Human Services.

ISR Immune System Regulation: Swedish immunotherapy firm’s subsidiary, ISR HBV, is conducting toxicological studies to determine whether its Immunolid ISR50 treatment could be used against COVID-19.

Kamada: Israeli pharmaceutical company is working on an antibody-based treatment for COVID-19 using the blood plasma of patients who recovered from the disease.

Kiniksa Pharmaceuticals: Bermuda-based pharmaceutical outfit announced positive early results from tests of its anti-inflammatory drug mavrilimumab on COVID-19 patients in Italy; new tests are planned in both Italy and the U.S.

Laurent Pharmaceuticals: Montreal-based biopharma company is planning to begin phase 2 clinical trials of its cystic fibrosis drug LAU-7b, or fenretide, as a treatment for COVID-19 on 200 patients in Canada and the U.S. by early May.

Mateon Therapeutics: Californian biopharma firm is testing a number of antiviral drugs as potential treatments for COVID-19, including the anti-malarial drug artemisinin, and submitted an application to the FDA in order to begin clinical trials on patients.

Merck KGaA: Darmstadt, Germany-based pharma multinational donated a supply of its multiple sclerosis drug interferon beta-1a to the French National Institute of Health and Medical Research in Paris for clinical trials on COVID-19 patients. The company’s North American life sciences arm, MilliporeSigma, is supplying several vaccine efforts with reagents and other essential raw products for vaccine development.

Mesoblast: Australian medical firm is working with authorities in the U.S., Australia, China and Europe to evaluate the use of its remestemcel-L drug to treat COVID-19.

Mylan: Pennsylvania-based pharmaceutical firm restarted production of hydroxychloroquine, a drug used to fight lupus, malaria and arthritis, at its West Virginia factory; the drug is being tested as a treatment for COVID-19 in human trials in New York.

Panoptes Pharma: Vienna, Austria biotech outfit is planning to begin trials of its eye disease drug PP-001 to treat COVID-19 patients; similar drugs, known as DHODH inhibitors, have shown promising results against COVID-19 in Wuhan, China.

Partner Therapeutics: Lexington, Massachusetts biotech startup began clinical trials of its bone marrow stimulant drug sargramostim on COVID-19 patients at University Hospital Ghent in Belgium.

PharmaMar: Spanish drugmaker is preparing to start clinical trials of its multiple myeloma drug plitidepsin to treat COVID-19 patients at several hospitals in Spain.

Pluristem Therapeutics: Haifa, Israel-based medical company is developing a cell-based therapy to treat COVID-19, announcing on March 30 it had dosed three Israeli patients under a compassionate use program, with plans to enroll more.

Pulmotect: Houston-based biotech company announced positive results from animal trials of its respiratory drug PUL-042 as a treatment for COVID-19.
Leonard Schleifer.

Leonard Schleifer. © 2016 Bloomberg Finance LP

Regeneron Pharmaceuticals: Westchester, New York biotech outfit, run by billionaires Leonard Schleifer and George Yancopoulos, is conducting clinical trials of its rheumatoid arthritis drug sarilumab, developed with French firm Sanofi, on patients in New York.

Ridgeback Therapeutics: Miami-based biotech company received FDA approval to begin human trials of its antiviral drug EIDD-2801 — which it developed with the Atlanta-based Drug Innovations at Emory, a company owned by Emory University — on COVID-19 patients in the U.S.

Roche: Swiss pharma titan, part-owned by billionaire Maja Oeri, is testing its arthritis drug tocilizumab to treat patients in China and received FDA approval to begin U.S. trials.

Roivant Sciences: Swiss pharma company is working with U.S. authorities to begin trials of its antibody treatment, gimsilumab, on COVID-19 patients.

Synairgen: Southampton, UK-based drugmaker began clinical trials of its SNG001 treatment on COVID-19 patients on March 31.

Takeda: Japanese medical firm is working on hyperimmune therapy using blood plasma from previously infected patients.

Teva Pharmaceuticals: Pharma multinational is ramping up production of hydroxychloroquine, which is being tested as a treatment for COVID-19 in human trials in New York.

Vir Biotechnology: The San Francisco-based firm is collaborating with a number of companies and institutions — Cambridge, Massachusetts-based biotech companies Biogen and Generation Bio; Chinese medical firm WuXi Biologics; Monrovia, California-based drugmaker Xencor; and the National Institutes of Health — to manufacture antibodies that could treat the virus; it’s also working with Massachusetts-based Alnylam Pharmaceuticals to develop RNA interference therapies. On April 6, British pharma giant GlaxoSmithKline purchased a stake in the company for $250 million, with the goal of collaborating on treatments for COVID-19.

XBiotech: Austin, Texas-based biopharma firm is working with the FDA and San Antonio-based nonprofit BioBridge Global to identify useful antibodies in the blood plasma of patients who have recovered from COVID-19.

Zhejiang Hisun Pharmaceuticals: Chinese pharmaceutical company announced positive results from trials of its flu drug favipiravir on COVID-19 patients in Shenzhen and Wuhan; the company is supplying the drug to authorities in China and several foreign countries.

Vaccines:

AJ Vaccines: Danish vaccine developer is working on a COVID-19 vaccine that could hit the market in 2021.

Altimmune: The company is developing a novel intranasal vaccine for the coronavirus, making it one of three firms based in Gaithersburg, Maryland — along with Emergent Biosolutions and Novavax — that’s working on treatments and vaccines for COVID-19.

Arcturus Therapeutics: San Diego-based vaccine maker is developing a COVID-19 vaccine with researchers at the Duke-National University of Singapore medical school in Singapore.

Biocad: Russian drug developer is researching a COVID-19 vaccine, with animal trials scheduled for late April.
Thomas and Andreas Struengmann.

Thomas and Andreas Struengmann. STOCK4B/GETTY IMAGES

BioNTech: German biotech firm backed by billionaire twins Thomas and Andreas Struengmann is working to develop a coronavirus vaccine in partnership with Pfizer and Fosun Pharma, chaired by billionaire Guo Guangchang.

CanSino Biologics: Tianjin, China-based pharma company is starting clinical trials for its COVID-19 vaccine, using the vaccine technology deployed to develop the Ebola vaccine.

CEL-SCI: Vienna, Virginia biotech company is working with the University of Georgia on a COVID-19 vaccine, building on previous work for an H1N1 flu vaccine.

Codagenix: Melville, New York biotech firm is teaming up with the Serum Institute of India to develop a live-attenuated COVID-19 vaccine, which uses a live but weakened form of the virus.
Dietmar Hopp.

Dietmar Hopp. Getty Images

CureVac: German firm, funded by billionaire Dietmar Hopp and the Bill and Melinda Gates Foundation, received $87 million from the European Commission to scale up development of its coronavirus vaccine.

Dyadic: Jupiter, Florida company is collaborating with the Israel Institute for Biological Research on both treatment and a vaccine against COVID-19, using the firm’s gene expression platform.

Dynavax: Emeryville, California vaccine maker is working with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland to develop a COVID-19 vaccine.

EpiVax: Providence-based immunology firm is working with the University of Georgia and Miramar, Florida biotech outfit Generex on separate COVID-19 vaccine efforts.

ExpreS2ion: Danish biotech company received a grant of nearly $1 million from the European Union to develop a vaccine for COVID-19.

FluGen: Madison, Wisconsin-based flu vaccine developer is working with Indian pharma company Bharat Biotech and virologists at the University of Wisconsin-Madison to develop a COVID-19 vaccine based on the company’s flu vaccine candidate.

GeneOne Life Science: South Korean vaccine maker is collaborating with researchers at Houston Methodist Hospital to develop an RNA vaccine for COVID-19.

GeoVax: Atlanta-based medical company is collaborating with Wuhan-based BioVax to jointly produce a COVID-19 vaccine.

GlaxoSmithKline: British pharma titan is partnering with CEPI and Chengdu, China-based Clover Pharmaceuticals to use its pandemic vaccine adjuvant platform — which boosts the immune response in patients receiving a shot — to speed up development of COVID-19 vaccines; on April 6, the company purchased a stake in San Francisco-based Vir Biotechnology for $250 million, with the goal of collaborating on treatments for COVID-19.

Greffex: Houston-based genetic engineering firm is preparing to begin animal trials for its COVID-19 vaccine.

Heat Biologics: North Carolina biopharma company is developing a COVID-19 vaccine with the University of Miami.

Hoth Therapeutics: New York-based biopharma firm is working with Voltron Therapeutics and Massachusetts General Hospital’s Vaccine and Immunotherapy Center to develop a COVID-19 vaccine.

iBio: Newark, Delaware biotech upstart is collaborating with Beijing-based CC-Pharming on the rapid development of a COVID-19 vaccine.

IMV: Canadian biopharma company will start animal testing of its COVID-19 vaccine candidate in April and May, with plans for human trials on subjects in Nova Scotia and Quebec.

Inovio: Plymouth Meeting, Pennsylvania biotech business is the second company to start human trials of a COVID-19 vaccine, announcing on April 6 it would begin testing in Philadelphia and Kansas City; the company also received $11.9 million in funding from the Department of Defense to rapidly produce the vaccine.

Johnson & Johnson: The company’s pharma unit, Janssen, will start manufacturing its vaccine — developed with the Department of Health and Human Services — this month, with human trials set to begin by September and a public rollout hoped for early 2021. The company and the federal government are investing more than $1 billion in the vaccine effort.

Medicago: Quebec City-based biotech company received more than $7 million from the Canadian and Quebec governments to fund development of its COVID-19 vaccine.

Moderna: Massachusetts biotech company, led by billionaire CEO Stéphane Bancel, was the first to begin human trials of its vaccine — on March 16 in Seattle — and could deploy it to health workers for emergency use by the fall.

Novavax: Maryland-based vaccine maker received $4 million in funding from CEPI to accelerate development of its vaccine candidates, with clinical trials expected in the late spring.

Sanofi: French medical firm is working with the federal government and Massachusetts-based Translate Bio to expedite its coronavirus vaccine, using technology previously used to develop one for SARS.

SK Group: South Korean conglomerate’s pharmaceutical arm, SK Bioscience, is conducting animal trials of its COVID-19 vaccine.

Sorrento Therapeutics: San Diego-based biotech firm is teaming up with Cambridge, MA gene therapy company SmartPharm Therapeutics to develop a gene-encoded COVID-19 vaccine; it’s also working with Chinese drugmaker Mabpharm on a fusion protein treatment for the disease.

Takis Biotech: Italian startup with just 25 employees is developing a vaccine with Stony Brook-based Applied DNA Sciences, with plans to begin human trials before the end of the year.

Themis Bioscience: Austrian biotech firm is part of a group, with the Institut Pasteur and the University of Pittsburgh, which received $4.9 million in initial funding from CEPI to build a COVID-19 vaccine modeled on the vaccine for measles.

Tonix Pharmaceuticals: New York-based pharma outfit is researching a potential COVID-19 vaccine based on the virus that causes horsepox.

Vaxart: San Francisco vaccine manufacturer Vaxart is working with Emergent Biosolutions to develop and manufacture an oral vaccine that can be taken as a tablet.

Vaxil: Israeli biotech startup began preclinical trials for its COVID-19 vaccine candidate.

VBI Vaccines: Massachusetts-based vaccine developer is collaborating with the National Research Council of Canada on a “pan-coronavirus” vaccine, which would target COVID-19 as well as SARS and Middle East respiratory syndrome, or MERS.

Protective Equipment And Sanitizer:

Anheuser-Busch InBev: The world’s largest beer company is making more than one million bottles of hand sanitizer from surplus alcohol at its breweries around the world.

Ansell: Australian protective equipment maker is expanding production capacity to meet higher demand for its biohazard suits and gloves.

Aria Designs: North Carolina furniture manufacturer received financing from CIT Group to procure millions of N95 surgical masks with its international suppliers.
Giorgio Armani.

Giorgio Armani. Courtesy of Giorgio Armani.

Armani: Billionaire Giorgio Armani’s luxury fashion brand converted all production at its Italian factories to manufacture single-use medical overalls on March 26.

Bacardi: The Bermuda-based spirits giant converted production at nine production facilities in Mexico, France, England, Italy, Scotland, Puerto Rico and the continental U.S. to make hand sanitizer.

Bauer Hockey: Canadian ice hockey equipment maker is partnering with Liverpool, New York lacrosse equipment manufacturer Cascade Maverik Lacrosse to produce face shields at factories in Quebec and New York.

BrewDog: Independent beermaker is making hand sanitizer at its distillery in Scotland.

Bulgari: The Italian luxury jeweler is manufacturing hand sanitizer with its fragrances partner, ICR, with plans to make hundreds of thousands of bottles by May.
Sandro Veronesi.

Sandro Veronesi. © 2015 Bloomberg Finance LP.

Calzedonia Group: Italian retail clothing group, owned by billionaire Sandro Veronesi, converted production at several plants in Italy and Croatia to manufacture masks and medical gowns, with initial production of 10,000 masks a day.

Cantabria Labs: Spanish health products and cosmetics firm converted production at one of its factories to make hand sanitizer.

Colgate: Consumer goods maker is coordinating with the WHO to make 25 million soap bars at five factories on three continents, which will be donated to authorities lacking supplies in the fight against COVID-19.

Consomed: Tunisian mask and medical equipment maker put all of its workers, more than 70% of which are reportedly women, on quarantine inside the company’s Kairouan factory to maximize production of protective gear.

Decathlon: Sporting goods empire founded by French billionaire Michel Leclercq partnered with Isinnova, a small engineering and design firm based in Italy, to convert snorkeling masks into respirators.

Diageo: The maker of Johnnie Walker whisky and Smirnoff vodka donated two million liters of ethyl alcohol, a byproduct of the distillation process, to hand sanitizer manufacturers.

ExxonMobil: Oil & gas multinational is partnering with the Atlanta-based Global Center for Medical Innovation to coordinate the manufacturing of face shields and masks with refillable filter cartridges; prototypes are awaiting FDA approval, with plans to eventually produce up to 40,000 masks and cartridges per hour.

Fanatics: Billionaire Michael Rubin’s online sportswear retailer converted its baseball jersey factory in Pennsylvania to make masks and gowns for medical workers.

Fiat Chrysler Automobiles: The multinational automaker announced on March 23 it would begin installing capacity to produce masks, which will be initially distributed in the U.S., Canada and Mexico.

Fippi: Italian diapers producer worked with the Lombardy region and the Polytechnic University of Milan to convert its factory to make up to 900,000 masks a day, which will go to frontline health workers facing a devastating outbreak in the region.

GelPro: Austin-based maker of floor mats shifted part of its factory in Waco to produce face shields, with the first batch of 500 shields donated to healthcare workers at the field hospital set up in New York City’s Central Park.

Gojo Industries: The Ohio-based maker of Purell, owned by a billionaire family, is prioritizing delivery of its ubiquitous hand sanitizers to health workers and first responders on the frontlines.

González Byass: Spanish spirits maker made three of its facilities and distilleries available to public health authorities for the production of hand sanitizer.

GVS: Family-owned Italian company is hiring more workers to expand production of ventilator filters and biohazard antivirus masks, destined for hospitals in Italy, the U.S. and China.

HP: The tech multinational is using its 3D printing centers in four cities — Barcelona, San Diego, Corvallis, Oregon and Vancouver, Washington — to make masks, face shields and ventilator parts.

IKEA: Swedish furniture retailer is reportedly working with suppliers to increase production of masks, hand sanitizers, visors and aprons; the company also opened a drive-through COVID-19 testing facility with the UK’s National Health Service at its store in the Wembley area of London.
James Ratcliffe.

James Ratcliffe. © 2019 Bloomberg Finance LP

Ineos: Billionaire James Ratcliffe’s chemical powerhouse Ineos is building a new hand sanitizer plant in the UK — which will be ready in just 10 days — to produce a million bottles a month, and plans to build another in Germany.

Jockey: Wisconsin-based underwear maker is working with McDonough, Georgia-based medical products manufacturer Encompass Group to make up to 50,000 isolation gowns a week.
Françoise Bettencourt-Meyers.

Françoise Bettencourt-Meyers. AFP via Getty Images

L’Oréal: French cosmetics giant, part-owned by billionaire Françoise Bettencourt Meyers and her family, converted production at its North American plants to make hand sanitizer.

LVMH: On March 15, the luxury goods conglomerate led by Bernard Arnault — the world’s third-richest person — converted production at its perfume plants in France to make antiseptic gel.

Massaflex: Italian mattress maker converted all production at its factory in Tuscany to make masks.

Medline: Northfield, Illinois family-owned manufacturer is ramping up production to supply medical masks, biohazard bags, surgical clothing and disinfectants to hospitals across the United States.

Menarini: Pharma firm, owned by Italian billionaire Massimiliana Landini Aleotti and her three children, converted a production line at its Florence factory to make disinfectant gel that will be distributed free of charge to Italy’s civil protection agency. The company is also working with Singapore-based Credo Diagnostics to distribute Credo’s new 20-minute coronavirus testing kit, which has been approvd by European regulators.

Miroglio Group: Italian fashion group converted production at its factories in the northwestern Italian region of Piedmont to make up to 100,000 masks a day.

O.C. Tanner: Salt Lake City, Utah cloud-based software and employee recognition firm converted part of its manufacturing — which normally makes custom awards and trophies — to make hundreds of masks and ventilator parts, with an initial batch donated to the University of Utah Health hospital.

Pernod Ricard: French spirit maker’s U.S. branch is producing hand sanitizer at four distilleries in Arkansas, Kentucky, Texas and West Virginia.

Prada: On March 23, the luxury fashion empire — led by billionaire couple Miuccia Prada and Patrizio Bertelli — announced it would convert production at its factory in Perugia to make 80,000 medical overalls and 110,000 masks for healthcare workers in the Tuscany region.

Procter & Gamble: Consumer goods giant is installing new production lines at five factories to make 45,000 liters of hand sanitizer a week; the company is also making face masks in China and will soon begin production at plants in North America, Europe, Africa and elsewhere in Asia.

Quicken Loans: Detroit-based mortgage lender, founded by billionaire Dan Gilbert, is planning to produce 500,000 masks a week in a partnership with Dearborn-based apparel firm Carhartt and the Detroit-area Industrial Sewing and Innovation Center.

Seamus Golf: Beaverton, Oregon-based golf equipment maker converted production to make more than 1,500 masks a day.

Siemens: German multinational’s U.S. unit is working with Georgia Tech to produce up 2,500 face shields a day for hospitals in the Atlanta area; the company also opened up its global 3D printing network for designers and suppliers of medical devices around the world, free of charge.

Starkey Hearing Technologies: Minnesota-based hearing aid maker, owned by billionaire Bill Austin, is reportedly partnering with custom components manufacturer Lakeview Industries to make about 150,000 face shields a day.

Top Glove: Malaysian medical glove maker, one of the world’s largest, is ramping up production and has donated more than 5 million gloves to authorities in China and Malaysia.

Volkswagen: German automaker’s U.S. arm is working with its fabric supplier, the French auto parts maker Faurecia, to convert production at a Faurecia plant in Mexico to make masks and gowns; an initial shipment of 70,000 masks and 5,000 gowns will be distributed to hospitals in the New York area. In Europe, the group’s various companies — including Lamborghini, SEAT, and Škoda — have been 3D printing face shields and masks for authorities in the Czech Republic, Germany, Italy and Spain.

Voodoo Manufacturing: Brooklyn-based 3D printing firm repurposed its manufacturing facility to make an initial 2,500 face shields a week; the first supplies will be delivered to the hard-hit Elmhurst Hospital Center in New York City.

Ventilators And Beds:

Airbus: The aircraft maker is part of a group of fifteen companies, the Ventilator Challenge UK Consortium, which is partnering to build at least 10,000 ventilators for the British government.

BAE Systems: British aerospace company is part of the Ventilator Challenge UK Consortium.

Bloom Energy: San Jose, California-based fuel cell maker is refurbishing unused and out-of-warranty ventilators in a partnership with Philadelphia-based appliance distributor Almo Corporation, which will then ship them to state agencies and hospitals across the U.S.

BreathDirect: Long Beach-based startup was recently established by Darren Saravis, CEO of medical device firm Nectar, to quickly produce 3,500 ventilators a week by May at $10,000 each.
James Dyson.

James Dyson. Dave Benett/Getty Images for Luxury Cave

Dyson: British billionaire James Dyson announced his vacuum cleaner and hand dryer firm would start designing and making 10,000 ventilators, with more to come.

Ford: Auto giant is working with 3M and General Electric’s healthcare unit to make ventilators, respirators and face shields at its manufacturing sites; Ford and GE Healthcare announced on March 30 that the companies would produce 50,000 ventilators by July 8 with plans to increase production to 30,000 a month.

General Motors: The auto titan announced on March 27 it would start building ventilators at its Kokomo, Indiana plant in a partnership with medical device maker Ventec Life Systems, as well as producing masks at a factory in Michigan. Hours later, President Donald Trump invoked the Defense Production Act to compel GM to "accept, perform and prioritize federal contracts for ventilators.” On April 8, the company was awarded a $489.4 million contract with the Department of Health and Human Services to to provide 30,000 ventilators by the end of August.

GKN Aerospace: British aerospace firm is a member of the Ventilator Challenge UK Consortium.

Hill-Rom: Batesville, Indiana healthcare equipment manufacturer more than doubled its production of ventilators, ICU beds and diagnostic monitors. The firm was also included in U.S. President Donald Trump’s order under the Defense Production Act, which will help the company “secure the supplies they need to build ventilators needed to defeat the virus.”

Inspiration Healthcare: British medical devices maker is part of the Ventilator Challenge UK Consortium.
Anand Mahindra.

Anand Mahindra. ASSOCIATED PRESS

Mahindra Group: Mumbai-based conglomerate, owned by billionaire Anand Mahindra and his family, announced it would begin producing ventilators at plants in India, reportedly pricing them at less than $100 each.

Malvestio: Italian maker of ICU and hospital beds is ramping up production by 30-40% to meet a surge in demand for its beds from hospitals in Italy.

Medtronic: Minnesota-based medical device maker publicly shared the design specifications for its basic ventilator model, with the goal of helping other companies quickly manufacture ventilators. The company was also included in President Trump’s order under the Defense Production Act.

Meggitt: British aerospace and defense components maker is a member of the Ventilator Challenge UK Consortium.

Penlon: Oxford-based medical device maker is part of the Ventilator Challenge UK Consortium.

Philips: The Dutch multinational is doubling production of pulmonary ventilators, with plans to quadruple it by the third quarter of 2020. The company was also included in President Trump’s order under the Defense Production Act; on April 6, the Department of Health and Human Services announced a $467 million contract with Philips to produce 2,500 ventilators by the end of May and 43,000 by the end of the year.

ResMed: San Diego-based medical equipment maker is planning to more than double its production of ventilators and increase output of masks more than tenfold. The firm was also included in President Trump’s order under the Defense Production Act.

Rolls-Royce: The luxury carmaker is a member of the Ventilator Challenge UK Consortium.

SIARE Engineering: Italy’s largest ventilator producer enlisted the help of Italian army technicians and employees from Fiat Chrysler and Ferrari to ramp up production.

Smiths Group: British engineering firm is part of the Ventilator Challenge UK Consortium.
Elon Musk.

Elon Musk. Anadolu Agency via Getty Images

SpaceX: Billionaire Elon Musk’s rocket company is making components for ventilators manufactured by Minnesota-based medical device maker Medtronic.

Tesla: Electric automaker, also cofounded by Elon Musk, made a prototype ventilator out of electric car parts.

Thales Group: French aerospace multinational is a member of the Ventilator Challenge UK Consortium.

Ultra Electronics: British defense systems provider is part of the Ventilator Challenge UK Consortium.

Vyaire Medical: Illinois-based respiratory equipment maker is scaling up production of ventilators and was also included in President Trump’s order under the Defense Production Act.

Xerox: Copying giant is partnering with Sacramento-based medical device manufacturer Vortran to scale up its production of ventilators to 40,000 a month in April and then between 150,000 and 200,000 a month by June.

Supporting Healthcare Workers And First Responders:
Airbnb cofounders Nathan Blecharczyk, Brian Chesky and Joe Gebbia.

Airbnb cofounders Nathan Blecharczyk, Brian Chesky and Joe Gebbia. Getty

Airbnb: The peer-to-peer home rental company, cofounded by billionaires Brian Chesky, Nathan Blecharczyk and Joe Gebbia, is providing housing for 100,000 COVID-19 responders in homes volunteered by Airbnb hosts around the world.

Anaplan: San Francisco-based planning software firm is providing free access to its platform for 90 days to nonprofits, government agencies, pharmaceutical companies, academic institutions, healthcare providers and others on the COVID-19 frontlines.

Carbyne: New York startup’s emergency response tool, backed by Peter Thiel’s VC fund, is being used by 911 responders in New Orleans to track patients by video screening callers.

EverBlock Systems: Modular building block maker built a temporary hospital to treat COVID-19 patients, using its plastic building blocks and wall units, at the Ernest N. Morial Convention Center in New Orleans.

Faculty: London-based AI firm is collaborating with the UK’s National Health Service to develop models and simulations to help the British government’s data response strategy to the pandemic.

First Due: Emergency response platform partnered with the International Association of Fire Chiefs and mapping software firm Esri, founded by billionaire Jack Dangermond, to build a national COVID-19 self-reporting system that will provide self-reported health data to first responders.

GlobeKeeper: Tel Aviv-based security app developer worked with Israel’s Health Ministry to launch a voluntary tracking app which allows users to report their exposure to COVID-19; the company is reportedly rolling out its own coronavirus-tracking app, named SAFE, in India next week with plans to expand to other countries.

GoPuff: Late-night delivery app popular with college students is pivoting to deliver essential supplies to healthcare workers at hospitals in Chicago, Philadelphia and Washington D.C.

Headspace: The meditation and mindfulness app is granting free access to its premium offering, Headspace Plus, to healthcare workers in the U.S. through the end of 2020.

Hyundai: Korean automaker is opening drive-through COVID-19 testing centers at 11 children’s hospitals in ten states and Washington, D.C. as well as providing $2.2 million in grants.

Inditex: The Spanish fast fashion giant behind Zara and other brands, majority-owned by billionaire Amancio Ortega, is making its logistics and procurement network available to the Spanish government to coordinate supply of materials needed to make masks, gloves, face shields and other protective equipment.

Intel: Tech giant cofounded by billionaire Gordon Moore is investing $40 million in a COVID-19 response and readiness initiative, which will help healthcare manufacturers use Intel’s AI and cloud computing tools to identify solutions to treat COVID-19.

Manna Aero: Irish drone food delivery startup is launching a trial of the world’s first drone delivery service to bring groceries and medicines to vulnerable people; the trial will begin in the small Irish village of Moneygall.

Medallia: San Francisco-based cloud computing firm offered its crowdsourcing platform free of charge to nonprofits for six months, with partners including Oxfam and the International Committee of the Red Cross.

NeuroFlow: Philadelphia-based mental health startup built a free online tool that helps users check their symptoms to see if they should get tested for COVID-19, as well as screening for signs of anxiety and providing mental health resources.

Palantir: Big data firm, cofounded and chaired by billionaire Peter Thiel, is working with the U.S. Centers for Disease Control and the UK’s National Health Service on coronavirus-tracking software based on its data gathering and analysis technology platform, Palantir Foundry.

Rave Mobile Safety: Massachusetts-based safety collaboration platform is providing its Smart911 service, which allows users to provide information to authorities by creating profiles on a mobile app, free of charge; the platform is being used by first responders tracking COVID-19 cases in New Orleans, Chicago, Long Island and Arkansas.

Speetar: Libyan telehealth platform, which helps doctors in diasporas treat patients in their countries of origin, is working with the Libyan Ministry of Health to track and treat COVID-19 patients in the country; the company is also in talks to expand to Egypt and Pakistan.

Uber: Ride-hailing app cofounded by billionaires Travis Kalanick and Garrett Camp pledged 10 million free rides and food deliveries for healthcare workers, senior citizens and others in need.

UiPath: AI software startup, founded by billionaire Daniel Dines, is offering its robotic process automation software for free to healthcare organizations and hospitals, freeing up nurses and staff to focus more on patients.

கேலிக்குறியவர்களே  அமெரிக்காவை கேலி செயது கொண்டிருக்கிற அவலம்....



அன்புடன்
மதுரைத்தமிழன்